Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 30Carcinoma, Hepatocellular 18Colorectal Neoplasms 17Stomach Neoplasms 12Esophageal Squamous Cell Carcinoma 10Neoplasm Metastasis 9Advanced Solid Tumor 9Squamous Cell Carcinoma of Head and Neck 7Lung Neoplasms 7Head and Neck Neoplasms 7Rectal Neoplasms 5Small Cell Lung Carcinoma 4Neoplasms 4Nasopharyngeal Carcinoma 4Melanoma 4Esophageal Neoplasms 4Solid Tumor 3Lymphoma, Follicular 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Biliary Tract Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma 2Hodgkin Disease 2

Interventions

Rituximab 86Cyclophosphamide 80Prednisone 47Doxorubicin 43Lenalidomide 37Vincristine 34Magnetic Resonance Spectroscopy 29polatuzumab vedotin 28Gemcitabine 26Etoposide 26Specimen Handling 25fludarabine 23Biopsy 21Oxaliplatin 20CT-P10 20glofitamab 16tafasitamab 15obinutuzumab 15ibrutinib 13fludarabine phosphate 13zanubrutinib 12axicabtagene ciloleucel 12Immunotherapy, Adoptive 12Ifosfamide 12venetoclax 11pembrolizumab 11deltacortene 11prednylidene 10Prednisolone 10Leukapheresis 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × tislelizumab × 1 year × Clear all
NCT04282018 2026-02-20

Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab

BeOne Medicines

Phase 1/2 Completed
97 enrolled 43 charts
LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05267054 2025-09-15

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab

BeiGene

Phase 1/2 Completed
53 enrolled 17 charts
Lymphoid

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡